Related Experiment Video

Updated: Sep 7, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.4K

Reno protective role of amlodipine in patients with hypertensive chronic kidney disease

Georgi Abraham1, A Almeida2, Kumar Gaurav3

  • 1Department of Nephrology, MGM Healthcare, Nelson Manickam Road, Aminjikarai, Chennai 6300028, India.

World Journal of Nephrology
|June 23, 2022
PubMed

Insights

Amlodipine (ALM), a calcium channel blocker, effectively manages hypertension in chronic kidney disease (CKD) patients. It controls blood pressure, reduces cardiovascular risks, and slows kidney disease progression, improving patient quality of life.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Chronic kidney disease (CKD) and hypertension (HTN) share a complex, bidirectional relationship, where declining renal function elevates blood pressure (BP), and sustained HTN accelerates kidney damage.
  • Effective management of HTN is crucial for slowing CKD progression and reducing cardiovascular disease (CVD) risk.
  • Calcium channel blockers (CCBs) are a key class of antihypertensive medications.

Purpose of the Study:

  • To evaluate the efficacy and safety of amlodipine (ALM), a dihydropyridine CCB, in managing hypertension among patients with chronic kidney disease.
  • To assess ALM's impact on blood pressure control, cardiovascular outcomes, and the progression of kidney disease.

Main Methods:

  • Review of clinical experiences and data regarding the use of amlodipine (ALM) as monotherapy and in combination with other antihypertensives.
  • Analysis of ALM's pharmacokinetic properties, including its long half-life, and its effects on 24-hour blood pressure control.
  • Comparison of ALM with other CCBs and antihypertensive agents in patients with CKD and renal impairment.

Main Results:

  • Amlodipine (ALM) demonstrates effective blood pressure control in patients with CKD, with minimal adverse effects.
  • ALM use is associated with a significant reduction in the risk of cardiovascular endpoints, particularly stroke, in patients with renal impairment.
  • The long half-life of ALM ensures sustained 24-hour BP control, contributing to a reduced progression of end-stage renal disease (ESRD).

Conclusions:

  • Amlodipine (ALM) is a safe and effective antihypertensive option for patients with chronic kidney disease (CKD).
  • Compared to other CCBs, ALM offers superior benefits in managing HTN, reducing cardiovascular risks, and preserving renal function.
  • ALM improves overall patient quality of life by effectively controlling blood pressure and mitigating disease progression.

Keywords:
AmlodipineChronic kidney diseaseCombination therapyEnd-stage-renal diseaseHypertensionMonotherapy

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.0K
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.4K

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
741
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
814
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
56
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
866
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
479